BioMarin Stock Jumps After Settling Yuviwel Patent Fight With Ascendis
BioMarin and Ascendis end all Yuviwel patent fights. Ascendis will pay 20% on U.S. sales and 18% in the EU, Brazil, and South Korea until 2030.
/ 6 items
#ASND↓
BMO Capital Initiates Coverage on 7 Biotech Stocks: Outperform Ratings for ALNY, ASND, BMRN & More
BMO Capital starts coverage on ALNY, ASND, BMRN, CATX & more with Outperform ratings and price targets. See full analyst insights and targets.
Vertex to Acquire Crinetics for $10 Billion in Major Rare Disease Expansion
The deal adds PALSONIFY (paltusotine) and late-stage CAH therapy to Vertex’s portfolio.
MBX Biosciences’ Canvuparatide Shows Solid One-Year Data but Misses Market Expectations
MBX reports 57% response at 1 year for canvuparatide in hypoparathyroidism with stable safety, but shares fell on modest results.
Ascendis Pharma Scores FDA Approval for Yuviwel – Weekly Injection to Boost Growth in Achondroplasia
FDA approves Ascendis Pharma's Yuviwel, the first once-weekly injection to boost growth in children 2+ with achondroplasia. Launch expected Q2 2026.
Ascendis Pharma Stock Jumps on Takeover Rumors
Ascendis Pharma shares rose 5% after new takeover speculation involving European pharmaceutical companies, according to market chatter.